As research reveals the intricacies of immunological interactions, our understanding of the pathogenetic mechanisms of autoimmune blood disorders is expanding, providing insights for development and use of targeted therapies. This session will focus on autoimmune cytopenias and the antiphospholipid antibody syndrome as they emerge in conditions of immune dysregulation, review the increasing number of available treatment options and consider the clinical studies investigating if the better rationalized treatments are also the safest and most effective.
Dr. Theodosia Kalfa will review the postulated pathogenetic mechanisms in idiopathic and secondary warm autoimmune hemolytic anemia (AIHA), report on the rare cases of DAT-negative AIHA and on cases associated with genetically defined immune dysregulation, and discuss standard treatments and new therapeutic approaches.
Dr. Rachael Grace will review the increasing number of options now available for second line therapy in chronic and/or refractory immune thrombocytopenia including thrombopoietin receptor agonists and monoclonal antibodies targeting B-lymphocytes, review the relevant clinical studies and discuss the considerations for treatment decisions in a paucity of data based on direct comparisons.
Dr. Wendy Lim will discuss the clinical challenges in predicting thrombotic risk in patients with antiphospholipid syndrome (APS) and expand on the available data for evaluation of risks, benefits, and optimal type and duration of thromboprophylaxis.